Shots: VALBIOTIS to receive ~$5.1M up front, ~$67.7 as development & commercial milestones and royalties on sales of therapy. Nestle to get exclusive global rights to commercialize TOTUM-63 in the […]readmore
Tags : Reducing
Shots: The US FDA’s approval is based on SUSTAIN study assessing Adakveo (5mg/kg, 2.5mg/kg) vs PBO in 198 patients in a ratio 1:1:1 aged ≥ 16yrs. with any genotype of […]readmore
Shots: The approval is based on P-III DECLARE-TIMI 58 study assessing Farxiga vs PBO in 17,000+ patients with T2D at risk of CV events, including patients with multiple CV risk […]readmore
Shots: The SMILE study involves assessing of MiniMed 640G system with SmartGuard technology vs insulin pump therapy without continuous glucose monitoring (CGM) in 153 adults with T1D, prone to severe […]readmore